Zai Lab Announces Presentations at June Conferences
Zai Lab Limited (NASDAQ: ZLAB) announced its participation in three upcoming virtual conferences in June. Dr. Samantha Du, the CEO, will present at the Jefferies Global Healthcare Conference on June 2, the Goldman Sachs Annual Global Healthcare Conference on June 11, and participate in a panel at the JP Morgan China Investor Conference on June 24. Webcasts will be available live and archived on Zai Lab's website. The company focuses on developing medicines for cancer, infectious, and autoimmune diseases, aiming to establish a global pipeline of innovative drug candidates.
- Participation in multiple high-profile virtual conferences, elevating visibility.
- Strong leadership represented by CEO Dr. Samantha Du, highlighting company expertise.
- None.
SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company will be presenting at the following upcoming virtual conferences in June. Details of the virtual conferences are as follows:
Jefferies Global Healthcare Conference 2020
Presentation: Tuesday, June 2, 2020 at 3:00 p.m. EDT
Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer
Goldman Sachs 41st Annual Global Healthcare Conference
Presentation: Thursday, June 11, 2020 at 9:40 a.m. EDT
Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer
JP Morgan China Investor Conference
Panel Discussion: Wednesday, June 24, 2020 at 8:00 a.m. CST
Presenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive Officer
Live webcasts of the conferences will be available under "Events & Presentations” in the “Investors Relations” section of Zai Lab’s website. Archived replays will be available for 90 days following the event.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
For more information, please contact:
ZAI LAB CONTACTS:
Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com
Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com
Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com
FAQ
What conferences is Zai Lab participating in June 2020?
Who is presenting for Zai Lab at the upcoming conferences?
Where can I find the live webcasts of Zai Lab's conference presentations?
What does Zai Lab focus on in its business?
